BioTissue Announces Formation of Medical Advisory Board to Advance Regenerative Ocular Therapies

BioTissue Holdings announced the formation of its new Medical Advisory Board to provide clinical expertise and strategic counsel to guide BioTissue’s ongoing innovation in ocular surface disease and related ophthalmic applications.

“Our mission has always been to transform patient outcomes in ophthalmology through regenerative therapies,” said Ted Davis, President and CEO of BioTissue. “This distinguished group of advisors brings unmatched clinical and research experience that will help us accelerate the development and adoption of evidence-based biologic solutions for patients with ocular surface disease and related conditions.”

Board Members

• Eric D. Donnenfeld, MD
  An internationally recognized leader in refractive, corneal, and cataract surgery, Dr. Donnenfeld has served as president of the American Society of Cataract and Refractive Surgery (ASCRS), the International Intraocular Implant Club (IIIC), and the Ocular Microbiology and Immunology Group (OMIG). His career-long dedication to advancing ophthalmic innovation brings a vital perspective on regenerative approaches for corneal and ocular surface disease.

• Marjan Farid, MD
  Clinical Professor and Vice Chair of Ophthalmology at UC Irvine’s Gavin Herbert Eye Institute, Dr. Farid specializes in corneal transplantation, limbal stem cell grafts, artificial corneas, and advanced ocular surface disease management. Her pioneering research in regenerative techniques directly complements BioTissue’s focus on innovation in corneal healing.

• Paul Karpecki, OD
  Director of Cornea & External Disease at the Kentucky Eye Institute, Dr. Karpecki is widely regarded as a leading authority on ocular surface disease and dry eye. As a prolific author and educator, he brings critical expertise in integrating regenerative biologics into optometric practice to improve patient outcomes.

• Francis Mah, MD
  Director of Cornea & External Disease and Co-Director of Refractive Surgery at Scripps Clinic, Dr. Mah is a leading authority on anterior segment surgery and ocular infectious disease. The current president of ASCRS, he has authored more than 100 publications, and his clinical insight aligns directly with BioTissue’s mission in regenerative ocular therapies.

• Selina McGee, OD, FAAO
  A respected optometric leader in ocular disease management, Dr. McGee has been recognized as OD of the South and OD of the Year in Oklahoma. She offers a clinician’s perspective on how innovative biologic therapies can be seamlessly integrated into daily optometric care for patients with ocular surface conditions.

For more information about BioTissue’s regenerative ocular therapies, visit biotissue.com/ocular.